Ipca Laboratories Ltd. Results

H1FY25 & Q2FY25 Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals company Ipca Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Standalone Net total Income up 8% at Rs 1827.94 crore. Consolidated Net total Income up 15% at Rs 2381.16 crore. Indian formulations income up 11% at Rs 940.51 crore. Exports Income up 6% at Rs 762.90 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.89% in Q2FY25 as against @ 20.86% in Q2FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) . @1.9.10% in Q2FY25 as against@ 17.64 % in Q2FY24. Standalone Net Profit at Rs 244.12 crore (after exceptional items) up 51%. Consolidated Net Profit at Rs 229.48 crore (after exceptional items) up 58%. The Board has declared an interim dividend of Rs 2/- per share (200%). H1FY25 Financial Highlights: Standalone Net Total Income up 6% at Rs 3409.19 crore. Consolidated Net Total Income up 21% at Rs 4494.40 crore. Indian formulations income up 11 % at Rs 1813.88 crore. Exports Income up 1 % at Rs 1353.76 crore. Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.59 % in FY25 as against @ 20.04 % in FY24. Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.83% in FY25 as against @ 18.05% in FY24. Standalone Net Profit at Rs 448.25 crore (after exceptional items) up 36%. Consolidated Net Profit at Rs 421.72 crore (after exceptional items) up 37%.

Q1FY25 Quarterly Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals company Ipca Laboratories announced Q1FY25 results: Standalone Net total Income up 3% at Rs 1,581.25 crore. Consolidated Net total Income up 30% at Rs 2,113.24 crore. Indian formulations income up 12% at Rs 873.37 crore. Exports Income down 4% at Rs 590.86 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.25% in Q1FY25 as against @19.13% in Q1FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.52 % in Q1FY25 as against @ 18.57 % in Q1FY24. Standalone Net Profit at Rs 204.13 crore (after exceptional items) up 23%. Consolidated Net Profit at Rs 192.24 crore (after exceptional items) up 18 %.

Q4FY24 Quarterly & FY24 Annual Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals company Ipca Laboratories announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Standalone Net total Income up 6% at Rs 1,525.72 crore. Consolidated Net total Income up 33% at Rs 2,051.93 crore. Indian formulations income up 13% at Rs 689.83 crore. Exports Income up 7% at Rs 731.38 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.50% in Q4 FY24 as against @ 11.75% in Q4 FY23. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items).@ 14.98% in Q4 FY24 as against @11.29% in Q4 FY23. Standalone Net Profit at Rs 64.76 crore (after exceptional items) down 24%. Consolidated Net Profit at Rs 59.59 crore (after exceptional items) down 22%. The Board has recommended final dividend of Rs 2/- per share (200%) FY24 Financial Highlights: Standalone Net Total Income up 6% at Rs 6,111 crore. Consolidated Net Total Income up 23% at Rs 7,829.81 crore. Indian formulations income up 12% at Rs 3,097.16 crore. Exports Income up 2% at Rs 2,707.70 crore. Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 19.29% in FY24 as against @ 16.22% in FY23 Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 16.72% in FY24 as against @ 15.35% in FY23 Standalone Net Profit at Rs 530.41 crore (after exceptional items) up 5%. Consolidated Net Profit at Rs 547.35 crore (after exceptional items) up 16%

Q3FY24 Quarterly & 9MFY24 Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals company Ipca Laboratories announced Q3FY24 & 9MFY24 results: Q3FY24 Financial Highlights: Standalone Net Total Income increased by 4% to Rs 1,523.72 crore. Consolidated Net Total Income surged by 32% to Rs 2,075.31 crore. Indian formulations income grew by 11% to Rs 779.61 crore. Exports Income rose by 1% to Rs 640.34 crore. Standalone EBITDA margin (before forex gain/loss and other income) stood at 18.55% in Q3FY24, compared to 15.77% in Q3FY23. Consolidated EBITDA margin (before forex gain/loss, other income, and exceptional items) stood at 16.12% in Q3FY24, compared to 15.00% in Q3FY23. Standalone Net Profit increased by 19% to Rs 136.94 crore. Consolidated Net Profit surged by 67% to Rs 179.88 crore. 9MFY24 Financial Highlights: Standalone Net Total Income grew by 6% to Rs 4,752.03 crore. Consolidated Net Total Income increased by 20% to Rs 5,777.88 crore. Indian formulations income rose by 12% to Rs 2,407.33 crore. Exports Income increased by 1% to Rs 1,976.32 crore. Standalone EBITDA margin (before forex gain/loss, other income, and Unichem acquisition cost) stood at 19.55% in 9MFY24, compared to 17.63% in 9MFY23. Consolidated EBITDA margin (before forex gain/loss, other income, Unichem acquisition cost, and exceptional items) stood at 17.34% in 9MFY24, compared to 16.64% in 9MFY23. Standalone Net Profit grew by 11% to Rs 465.65 crore. Consolidated Net Profit increased by 24% to Rs 487.76 crore.